Back Back
Cell No. : Cell Name
RCB2536 : T24  update : 2021/05/20
CommentHuman cell line derived from bladder cancer. Transitional cell carcinoma. TKG0443 (Deposited from Tohoku Univ.).
Comment from the depositor
Terms and conditionsThere is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (
Basic information Depositor Fukuda, Hiroshi
Originator Bubenick, J.
Year of deposit 2007
Original cell TKG0443
Animal _human < Mammals
Genus Homo
Species sapiens
Gender Female
Age at sampling 81 years
Tissue bladder
Disease name transitional-cell carcinoma
Classification cancer
History Cell Resource Center for Biomedical Research, Tohoku University(TKG0443)
Lifespan infinite
Morphology epithelial-like
Cellosaurus(Expasy) CVCL_0554
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Medium and additives MEM + 10% FBS
Antibiotics Free
Passage method 0.25% trypsin
Culture information Passage ratio 1 : 8 split
SC frequency Subculture : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
Isozyme LD, NP
STR(human) OK
deposit info
lot info
Reference information Reference 3
User's Publication 4

To topTop
4680  Capon DJ, Chen EY, Levinson AD, Seeburg PH, Goeddel DV.  Complete nucleotide sequences of the T24 human bladder carcinoma oncogene and its normal homologue.  Nature  1983  302:33-7  PubMed ID: 6298635
1173  Bubeník J, Baresová M, Viklický V, Jakoubková J, Sainerová H, Donner J.  Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen.  Int J Cancer  1973  11(3):765-73  PubMed ID: 4133950
1172  Bubeník J, Perlmann P, Helmstein K, Moberger G.  Cellular and humoral immune responses to human urinary bladder carcinomas.  Int J Cancer  1970  5(3):310-9  PubMed ID: 5452065

To topTop
User's Publication
13009  Tajima Y, Toyoda T, Hirayama Y, Matsushita K, Yamada T, Ogawa K, Watanabe K, Takamura-Enya T, Totsuka Y, Wakabayashi K, Miyoshi N.  Novel o-Toluidine Metabolite in Rat Urine Associated with Urinary Bladder Carcinogenesis.  Chem Res Toxicol  2020    PubMed ID: 32343562
13311  Sugiyama T, Ozono S, Miyake H.  Expression Profile of S100A2 and its Clinicopathological Significance in Renal Cell Carcinoma.  Anticancer Res  2020    PubMed ID: 33109571
13329  Matsumura E, Kosuge N, Nakanishi S, Suda T, Sugawa A, Fujimura T, Miyagi R, Yoshimi N, Saito S.  Urine Lactoferrin as a Potential Biomarker Reflecting the Degree of Malignancy in Urothelial Carcinoma of the Bladder.  Tohoku J Exp Med  2020    PubMed ID: 33162487
14268  Yamashita T, Higashi M, Momose S, Morozumi M, Tamaru JI.  Nuclear expression of Y box binding-1 is important for resistance to chemotherapy including gemcitabine in TP53-mutated bladder cancer  Int J Oncol  2017  51(2):579-586  PubMed ID: 28714514

Back Back Return Top Page